References
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005:105:2640–2653.
- Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007:249:121–132.
- Terry EN, Gann PH, Molokie R, et al. Changes in the activity of the gpx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. Leuk Res 2012:35:831–833.
- Reinke EN, Ekoue DN, Bera S, et al. Translational regulation of gpx-1 and gpx-4 by the mtor pathway. PLoS One 2014:9:e93472.
- Dhar SK, St Clair DK. Manganese superoxide dismutase regulation and cancer. Free Radic Biol Med 2012:52:2209–2222.
- Hollinshead M, Meijer J. Immunocytochemical analysis of soluble epoxide hydrolase and catalase in mouse and rat hepatocytes demonstrates a peroxisomal localization before and after clofibrate treatment. Eur J Cell Biol 1988:46:394–402.
- Maiorino M, Thomas JP, Girotti AW, et al. Reactivity of phospholipid hydroperoxide glutathione peroxidase with membrane and lipoprotein lipid hydroperoxides. Free Radic Res Commun 1991;12–13:131–135.
- Kokoglu E, Aktuglu G, Belce A. Leucocyte superoxide dismutase levels in acute and chronic leukemias. Leuk Res 1989:13:457–458.
- Ciarcia R, d’Angelo D, Pacilio C, et al. Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (cml) cells. J Cell Physiol 2010:224:443–453.
- Ahmad R, Singh R, Tripathi AK, et al. Leukocyte superoxide dismutase activity in patients with chronic myeloid leukemia. Rev Bras Hematol Hemoter 2012:34:394–395.
- Eisele L, Klein-Hitpass L, Chatzimanolis N, et al. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol 2007:117:8–15.
- Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ros-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009:8:579–591.
- Zhang H, Trachootham D, Lu W, et al. Effective killing of gleevec-resistant cml cells with t315i mutation by a natural compound peitc through redox-mediated mechanism. Leukemia 2008:22:1191–1199.
- Liu L, Chen R, Huang S, et al. Knockdown of sod1 sensitizes the cd34 + cml cells to imatinib therapy. Med Oncol 2011:28:835–839.
- Koptyra M, Falinski R, Nowicki MO, et al. Bcr/abl kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319–327.
- Kim A. Modulation of mnsod in cancer: epidemiological and experimental evidence. Toxicol Res 2010:26:83–93.